Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Park, W.K., Kennedy, R.M., Larsen, S.D., Miller, S., Roth, B.D., Song, Y., Steinbaugh, B.A., Sun, K., Tait, B.D., Kowala, M.C., Trivedi, B.K., Auerbach, B., Askew, V., Dillon, L., Hanselman, J.C., Lin, Z., Lu, G.H., Robertson, A., Sekerke, C.(2008) Bioorg Med Chem Lett 18: 1151-1156
- PubMed: 18155906 
- DOI: 10.1016/j.bmcl.2007.11.124
- Primary Citation of Related Structures:  
3BGL - PubMed Abstract: 
4-Sulfamoyl pyrroles were designed as novel hepatoselective HMG-CoA reductase inhibitors (statins) to reduce myalgia, a statin-induced adverse effect. The compounds were prepared via a [3+2] cycloaddition of a Münchnone with a sulfonamide-substituted alkyne ...